ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.8573A>G (p.Gln2858Arg) (rs80359114)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000131683 SCV000186719 likely benign Hereditary cancer-predisposing syndrome 2018-02-05 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Other data supporting benign classification,Co-occurence with a mutation in another gene that clearly explains a proband's phenotype
Breast Cancer Information Core (BIC) (BRCA2) RCV000113963 SCV000147404 uncertain significance Breast-ovarian cancer, familial 2 2002-05-29 no assertion criteria provided clinical testing
Color RCV000131683 SCV000902975 likely benign Hereditary cancer-predisposing syndrome 2015-12-28 criteria provided, single submitter clinical testing
Counsyl RCV000113963 SCV000785686 likely benign Breast-ovarian cancer, familial 2 2017-11-01 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000656806 SCV000227605 uncertain significance not provided 2015-01-23 criteria provided, single submitter clinical testing
GeneDx RCV000656806 SCV000210478 uncertain significance not provided 2018-01-03 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.8573A>G at the cDNA level, p.Gln2858Arg (Q2858R) at the protein level, and results in the change of a Glutamine to an Arginine (CAA>CGA). This variant, also known as BRCA2 8801A>G using alternate nomenclature, was observed in 2 families with multiple cases of breast and/or ovarian cancer and has been reported in combination with a pathogenic BRCA1 variant, Glu352Ter (Simard 2007, Spurdle 2008). This variant was also observed in an individual with oropharyngeal cancer diagnosed before age 50 (Chandrasekharappa 2017). In a large case-control analysis, BRCA2 Gln2858Arg was not significantly associated with breast cancer (Shimelis 2017). In addition, this variant was predicted to be likely not pathogenic based on tumor pathology, clinical histories, family studies and co-occurrence with deleterious variants (Spurdle 2008, Lindor 2012). BRCA2 Gln2858Arg was not observed at a significant frequency in large population cohorts (Lek 2016). This variant is located in the DNA binding domain (Yang 2002). In-silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether BRCA2 Gln2858Arg is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Invitae RCV000045562 SCV000073575 likely benign Hereditary breast and ovarian cancer syndrome 2018-01-22 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000113963 SCV000296596 uncertain significance Breast-ovarian cancer, familial 2 2016-05-25 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.